OBJECTIVES: Assessment of patient’s perspectives of hypoglycemia burden may be of value to provide adequate management of type 2 diabetes (T2D) patients. The Hypoglycemia Perspectives Questionnaire (HPQ) is a new multidimensional instrument assessing patient’s experience of hypoglycemia. The goal of this study was to test the practicability and utility of HPQ-Russian version (HPQ-R) by means of its psychometric performance. METHODS: A total of 200 T2D patients receiving oral hypoglycemic therapy (59% – metformin; 41% – metformin plus vildagliptin or sulphonylureas, SU) were enrolled in the study: male/female 71/129; mean age – 58.7 yrs; mean disease duration – 4.1 yrs. Mean HbA1c level was 7%. All the patients completed HPQ-R at baseline and after 2-3 months of treatment. Patients and physicians were interviewed to test practicability of the instrument. Construct validity, reliability and sensitivity of the HPQ-R were assessed to provide its utility. RESULTS: Both patients and physicians acknowledged the comprehensiveness of the tool for revealing hypoglycemia-related problems; physicians used information from it for their decision-making. It was easily understood by, and administered to patients: 2.8% of missing values. An exploratory factor analysis revealed a strongly dimensional instrument (explained 70% of total pooled variance), with Chronbach alphas ≥0.9 for 6 out of 7 scales. Reproducibility of the tool was shown by comparing HPQ-R scores at two time-points for patients with effective HbA1c control receiving metformin plus vildagliptin: r=0.53–0.87 for 5 scales (p<0.05). HPQ-R scores were lower in patients with hypoglycemia events than in patients without hypoglycemia as well as in patients with severe hypoglycemia than in patients with non-severe hypoglycemia (p<0.05). Increased occurrence of hypoglycemia events and worsening of scores for 4 HPQ scales was shown after switch from monotherapy to therapy metformin plus SU (p<0.05). CONCLUSIONS: Thus, the HPQ-R is a practical and useful tool for comprehensive assessment of hypoglycemia experience in T2D patients.